The company discontinued developing emugrobart after two studies showed the drug didn’t achieve intended outcomes.
To study this transformation, we compile a comprehensive, synchronized database spanning the pharmaceutical drug development supply chain, covering scientific publications, clinical trials, drug ...
Chugai Pharmaceutical Co. fell 7.3%, the largest intraday decline since August 2025, after the company said it had ended the ...
The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
StockStory.org on MSN
Q4 earnings highs and lows: Azenta (NASDAQ:AZTA) vs the rest of the drug development inputs & services stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...
FDA’s NAM framework emphasizes context of use, human biological relevance, technical characterization, and fit-for-purpose ...
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...
Roche's rollout of thousands of Nvidia chips is the latest example of a pharmaceutical giant trying to use AI to discover and ...
JACKSONVILLE, Fla.--(BUSINESS WIRE)-- Redwire Corporation (RDW), a leader in space infrastructure for the next-generation space economy, has been awarded a NASA contract to launch four additional ...
In 2022, the combined research and development (R&D) expenditure of the U.S. pharmaceutical industry consisted of more than $100 billion. While this is a significantly expansive market, approximately ...
Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027Vancouver, British ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results